Nanomedicines and the future of glioma

Aikaterini Lalatsa, Diana Moreira Leite, Geoffrey John Pilkington

Research output: Contribution to journalArticlepeer-review

154 Downloads (Pure)

Abstract

There is a higher incidence of brain tumours in the UK than the world average for both men (8.1 per 100,000), and women (5.3 per 100,000). Malignant gliomas are the most common primary brain tumours of which glioblastoma (GBM) is the most prevalent. GBM is also known to be the most biologically aggressive and cellularly heterogeneous and is highly diffusively infiltrative in nature which renders surgical excision impossible without causing significant neurological deficit. Typically, following surgery, patients undergo a course of radiotherapy or a combination of chemo/radiotherapy (Stupp protocol). However, despite surgical debulking and improvements in radio- and chemotherapies, the prognosis of patients with GBM remains extremely poor, with a median survival time of only 14.5 months from diagnosis to death.
Original languageEnglish
Pages (from-to)51-57
JournalOncology News
Volume10
Issue number2
Publication statusPublished - May 2015

Keywords

  • Nanomedicine
  • Glioblastoma Multiforme

Fingerprint

Dive into the research topics of 'Nanomedicines and the future of glioma'. Together they form a unique fingerprint.

Cite this